Market Overview

FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status in November Report - Bloomberg

Share:
Related AMRN
Benzinga's Top Initiations
Amarin Offers New Clinical, Pre-Clinical Data at ACC Meeting Related to Effect of EPA Therapy in Statin-Treated Patients

View Orange Book.

Posted-In: News FDA

 

Related Articles (AMRN)

View Comments and Join the Discussion!